Lifastuzumab vedotin
Product Specifications
CAS Number
1401812-88-1
Target
Antibody-Drug Conjugates (ADCs), Others
Related Pathways
Others, Antibody-drug Conjugate/ADC Related
Bioactivity
Lifastuzumab vedotin (DNIB0600A), an antibody-drug conjugate (ADC), consists of a humanized IgG1 monoclonal antibody targeting NaPi2b (MNIB2126A) linked to the potent antimitotic agent monomethyl auristatin E (MMAE), which disrupts cell division by inhibiting tubulin polymerization. This compound shows promise for research in non-small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (PROC) [1].
Shipping Conditions
Ice Packs
Storage Temperature
-20°C
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC470040-100 1x 100 µL
CD35 / CR1 (E11), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC471739-500 1x 500 µL
P53 Tumor Suppressor Protein (TP53/1739), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details